[Adobe Stock]
Pharma companies like Jazz (Epidiolex) and AbbVie already have cannabinoid programs. This could accelerate M&A or partnerships.
Rescheduling could also redraw the competitive map by making FDA-style drug development the clearest federal pathway. Big pharma has already demonstrated there is a playbook for cannabinoids when the molecule, dosing, and endpoints fit FDA norms. Jazz Pharmaceuticals completed its acquisition of GW Pharmaceuticals in 2021, inheriting Epidiolex and the infrastructure behind one of the most successful cannabinoid drug development efforts to date. That template could accelerate partnerships, licensing deals, and acquisitions around purified, standardized cannabinoids that can survive Phase II and Phase III trials, not necessarily around plant-scale cultivation.
Moving from Schedule I to Schedule III lowers practical barriers that have made U.S. clinical work slow, expensive, and hard to standardize. It also clarifies what “success” looks like federally: controlled substances in Schedule III can be lawfully dispensed by prescription, but any marijuana-derived product would still have to comply with the Food, Drug, and Cosmetic Act and clear FDA requirements before it could be legally marketed. As Adam Stettner, CEO of FundCanna, put it in a statement circulating among industry advocates: “It also unlocks long-blocked research pathways, enabling rigorous clinical studies, standardized formulations, and a new era of product innovation.”
That new era would come with a harder test of claims the industry has marketed for years. The risk-benefit picture is genuinely messy, especially on mental health. Federal health agencies and major reviews have flagged links between heavy use and psychosis risk, concerns about adolescent exposure, and the reality of cannabis use disorder, even as they also note therapeutic promise in narrower lanes. On the “clean evidence” side, Epidiolex remains the clearest FDA-level example: a purified cannabidiol product indicated for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome or tuberous sclerosis complex.
The shift would also land on top of a national patchwork. Recreational cannabis is legal in 24 states, and medical marijuana is legal in more than 40 states plus Washington, D.C., depending on how states’ “medical” programs are defined. Public opinion is broadly permissive even as it has cooled from recent highs. Gallup’s annual Crime poll (conducted Oct. 1 to 16, 2025) found 64% of U.S. adults say marijuana use should be legal, down from the 68% to 70% range Gallup recorded from 2020 to 2024.
Filed Under: Drug Discovery
